If stomach paralysis is not treated, it can lead to malnutrition, dehydration, the formation of a hard mass in the stomach (a bezoar), and many other health complications
More frequent monitoring may be needed if symptoms of thyroid dysfunction develop
In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism, participants who stopped semaglutide after losing 17.3% of their body weight regained about two-thirds of that loss within a year of stopping, though they still remained, on average, 5.6% below their starting weight even a year later
Research peptide vendors sell retatrutide labeled 'for research use only.' These products are not manufactured to pharmaceutical standards and are not tested or regulated by the FDA
All handling should be conducted by qualified researchers in accordance with applicable regulations